1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult ParticipantsSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorderRecruitingPhase 12025-12-19NCT07258745